Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-23T12:07:11.890Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Perspectives on the Combination of D-Cycloserine and Cognitive-Behavioral Therapy for the Treatment of Anxiety Disorders

Published online by Cambridge University Press:  07 November 2014

Michael W. Otto ,
Shawnee L. Basden ,
Teresa M. Leyro ,
R. Kathryn McHugh  and
Stefan G. Hofmann
Get access Rights & Permissions [Opens in a new window]

Abstract

In a particular success for translational research agendas, characterization of the neuronal circuits underlying fear extinction, and basic research in animal extinction paradigms, has led to intervention studies examining the use of D-cycloserine (DCS) to enhance therapeutic learning from exposure-based cognitive-behavioral therapy (CBT). In this article, we review these intervention studies, and discuss DCS augmentation of CBT relative to more traditional combination-treatment strategies in the treatment of anxiety disorders. We offer an accounting, based on evidence for internal context effects, of current limitations in the combination of antidepressant or benzodiazepine medications with CBT and discuss the advantages of isolated-dosing strategies with DCS relative to these limitations. This strategy is contrasted with the chronic-dosing applications of DCS for schizophrenia and Alzheimer's disease, and future directions for isolated-dosing strategies are discussed.

Type
Review Articles
Information
CNS Spectrums , Volume 12 , Issue 1 , January 2007 , pp. 51 - 61
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Foa, EB, Franklin, ME, Moser, J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry. 2002;10:987–997.CrossRefGoogle Scholar
2.Otto, MW, Smits, JAJ, Reese, HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clinical Psychology: Science and Practice. 2005;12:72–86.Google Scholar
3.Davidson, JR, Foa, EB, Huppert, JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004;61:1005–1013.CrossRefGoogle ScholarPubMed
4.Foa, EB, Liebowitz, MR, Kozak, MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162:151–161.CrossRefGoogle ScholarPubMed
5.van Balkom, AJ, de Haan, E, van Oppen, P, et al. Cognitive and behavioral therapies alone and in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis. 1998;186:492–499.CrossRefGoogle ScholarPubMed
6.Franklin, ME, Abramowitz, JS, Bux, DA, Zoellner, LA, Feeny, NC. Cognitive-behavioral therapy with and without medication in the treatment of obsessive-compulsive disorder. Professional Psychology: Research and Practice. 2002;33:162–168.CrossRefGoogle Scholar
7.Kampman, M, Keijsers, GP, Hoogduin, CA, Hendriks, GJ. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry. 2002;63:772–777.CrossRefGoogle ScholarPubMed
8.Otto, MW, Pollack, MH, Penava, SJ, Zucker, BG. Cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav Res Ther. 1999;37:763–770.CrossRefGoogle ScholarPubMed
9.Heldt, E, Gus Manfro, G, Kipper, L, Blaya, C, Isolan, L, Otto, MW. One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: outcome and predictors of remission. Behav Res Ther. 2006;44:657–665.CrossRefGoogle ScholarPubMed
10.Barlow, DH, Gorman, JM, Shear, MK, Woods, SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA. 2000;283:2529–2536.CrossRefGoogle ScholarPubMed
11.de Beurs, E, van Balkom, AJ, Lange, A, Koele, P, van Dyke, R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry. 1995;152:683–691.Google ScholarPubMed
12.Furukawa, TA, Watanabe, N, Chruchill, R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia. Br J Psychiatry. 2006;188:305–312.CrossRefGoogle ScholarPubMed
13.Marks, IM, Swinson, RP, Basaglu, M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry. 1993;162:776–787.CrossRefGoogle ScholarPubMed
14.Powers, MB, Smits, JAJ, Leyro, TM, Otto, M. Translational research perspectives on maximizing the effectiveness of exposure therapy. In: Richard, DCS, Lauterbach, D, eds. Comprehensive Handbook of the Exposure Therapies. Orlando, FL: Academic Press; 2006:109–126.Google Scholar
15.Bouton, ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry. 2002;52:976–986.CrossRefGoogle ScholarPubMed
16.Bouton, ME. Context and behavioral processes in extinction. Learn Mem. 2004;11:485–494.CrossRefGoogle ScholarPubMed
17.Bouton, ME, Kenney, FA, Rosengard, C. State dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci. 1990;104:44–55.CrossRefGoogle ScholarPubMed
18.Rescorla, RA. Experimental extinction. In: Mowrer, RR, Klein, SB, eds. Handbook of Contemporary Learning Theories. Mahwah, NJ: Erlbaum; 2001:119–154.Google Scholar
19.Mystkowski, JL, Mineka, S, Vernon, LL, Zinbarg, RE. Changes in caffeine states enhance return of fear in spider phobia. J Consult Clin Psychol. 2003;71:243–250.CrossRefGoogle ScholarPubMed
20.Foa, EB, Kozak, MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986;99:20–35.CrossRefGoogle ScholarPubMed
21.Powers, MB, Smits, JA, Telch, MJ. Disentangling the effects of safety-behavior utilization and safety-behavior availability during exposure-based treatment: a placebo-controlled trial. J Consult Clin Psychol. 2004;72:448–454.CrossRefGoogle ScholarPubMed
22.Kamphuis, JH, Telch, MJ. Effect of distraction and guided threat reappraisal on fear reduction during exposure-based treatments for specific fears. Behav Res Ther. 2000;38:1163–1181.CrossRefGoogle ScholarPubMed
23.Rodriguez, BI, Craske, MG. The effects of distraction during exposure to phobic stimuli. Behav Res Ther. 1993;31:549–558.CrossRefGoogle ScholarPubMed
24.Otto, MW, Pollack, MH, Sabatino, SA. Maintenance of remission following cognitive-behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment. Behav Ther. 1996;27:473–482.CrossRefGoogle Scholar
25.Davis, M, Falls, WA, Gewirtz, J. Neural systems involved in fear inhibition: extinction and conditioned inhibition. In: Myslobodsky, M, Weiner, I, eds. Contemporary Issues in Modeling Psychopathology. Boston, Mass: Kluwer Academic Publishers; 2000:113–142.CrossRefGoogle Scholar
26.Davis, M, Myers, KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry. 2002;52:998–1007.CrossRefGoogle ScholarPubMed
27.Davis, M, Myers, KM, Ressler, KJ, Rothbaum, BO. Facilitation of extinction of conditioned fear by D-cycloserine: implications for psychotherapy. Current Directions in Psychological Science. 2005;14:214–219.CrossRefGoogle Scholar
28.Richardson, R, Ledgerwood, L, Cranney, J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem. 2004;11:510–516.CrossRefGoogle ScholarPubMed
29.Ledgerwood, L, Richardson, R, Cranney, J. D-cycloserine facilitates extinction of learned fear: effects of reacquisition and generalized extinction. Biol Psychiatry. 2005;57:841–847.CrossRefGoogle ScholarPubMed
30.Ressler, KJ, Rothbaum, BO, Tannenbaum, L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobics to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136–1144.CrossRefGoogle ScholarPubMed
31.Nair, K, Epstein, I, Baron, H, Mulinos, M. Absorption, distribution, and excretion of cycloserine in man. Antibiot Ann. 1956:136–140.Google Scholar
32.D'Souza, DC, Gil, R, Cassello, K, et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry. 2000;47:450–462.CrossRefGoogle ScholarPubMed
33.Hofmann, SG, Meuret, AE, Smits, JAJ, et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63:298–304.CrossRefGoogle ScholarPubMed
34.Katzelnick, DJ, Kobak, KA, DeLeire, T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158:1999–2007.CrossRefGoogle ScholarPubMed
35.Schneier, FR, Heckelman, LR, Garfinkel, R, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322–331.Google ScholarPubMed
36.Heresco-Levy, U, Kremer, I, Javitt, DC, et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol. 2002;5:301–307.CrossRefGoogle ScholarPubMed
37.van Berckel, BN, Lipsch, C, Timp, S, et al. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology. 1997;16:317–324.CrossRefGoogle ScholarPubMed
38.van Berckel, BN, Lipsch, C, Gispen-de Wied, C, et al. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl). 1998;138:190–197.CrossRefGoogle ScholarPubMed
39.Physicians Desk Reference. 60th ed. Montvale, NJ: Thomson PDR: 2006.Google Scholar
40.Quartermain, D, Mower, J, Rafferty, MF, Herting, RL, Lanthorn, TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;157:7–12.CrossRefGoogle Scholar
41.Parnas, AS, Weber, M, Richardson, R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem. 2005;83:224–231.CrossRefGoogle ScholarPubMed
42.Boje, KM, Wong, G, Skolnick, P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res. 1993;603:207–214.CrossRefGoogle ScholarPubMed
43.Randolph, C, Roberts, JW, Tierney, MC, Bravi, D, Mouradian, MM,Chase, TN. D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 1994;8:198–205.CrossRefGoogle ScholarPubMed
44.Tuominen, HJ, Tiihonen, J, Wahlbeck, K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Res. 2005;72:225–234.CrossRefGoogle ScholarPubMed
45.Evins, AE, Amico, E, Posever, TA, Toker, R, Goff, DC. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Res. 2002;56:19–23.CrossRefGoogle ScholarPubMed
46.Goff, DC, Tsai, G, Manoach, DS, Coyle, JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms of schizophrenia. Am J Psychiatry. 1995;152:1213–1215.Google Scholar
47.Goff, DC, Coyle, JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158:1367–1377.CrossRefGoogle ScholarPubMed
48.Goff, DC, Tsai, G, Levitt, J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1996;56:21–27.CrossRefGoogle Scholar
49.Duncan, EJ, Szilagyi, S, Schwartz, MP, et al. Effects of D-cycloserine on negative symptoms of schizophrenia. Schizophrenia Res. 2004;71:239–248.CrossRefGoogle Scholar
50.Goff, DC, Herz, L, Posever, T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychpharmacology. 2005;179:144–150.CrossRefGoogle ScholarPubMed
51.Goff, DC. Tsai, G, Manoach, DS, et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153:1628–1630Google ScholarPubMed
52.van Berckel, BN, Hijman, R, van der Linden, JA, Westenberg, HG, van Ree, JM, Kahn, RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996;40:1298–1300.CrossRefGoogle ScholarPubMed
53.Heresco-Levy, U, Javitt, DC, Ermilov, M, Silipo, G, Shimoni, J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 1998;1:131–135.CrossRefGoogle ScholarPubMed
54.Goff, DC, Henderson, DC, Evins, E, Amico, E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;45:512–514.CrossRefGoogle ScholarPubMed
55.Heresco-Levy, U, Ermilov, M, Shimoni, J, Shapira, B, Silipo, G, Javitt, DC. Placebo-controlled trial of D-cylcoserine added to cconventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002;159:480–482.CrossRefGoogle ScholarPubMed
56.Rosse, RB, Fay-McCarthy, M, Kendrick, K, Davis, RE, Deutsch, SI. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol. 1996;19:444–450.CrossRefGoogle ScholarPubMed
57.van Berckel, BN, Evenblij, CN, van Loon, AM, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21:203–210.CrossRefGoogle ScholarPubMed
58.Yurgelun-Todd, DA, Coyle, JTGruber, SA, et al. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005;138:23–31.CrossRefGoogle ScholarPubMed
59.Tsai, GE, Falk, WE, Gunther, J, Coyle, JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999;156:467–469.CrossRefGoogle ScholarPubMed
60.Fakouhi, TD, Jhee, SS, Sramek, JJ, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol. 1995;8:226–230.CrossRefGoogle ScholarPubMed
61.Tsai, GE, Falk, WE, Gunther, J. A preliminary study of d-cycloserine treatment in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1998;10:224–226.CrossRefGoogle ScholarPubMed
62.Laake, JR, Oeksengaard, AR. D-cycloserine for Alzheimer's disease. (Cochrane Review). The Cochrane Database of Systematic Reviews. 2002, Issue 2. Art. No.: CD003153. DOI:10.1002/14651858.CD003153.Google Scholar
63.Ledgerwood, L, Richardson, R, Cranney, J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci. 2003;117:341–349.CrossRefGoogle ScholarPubMed
64.Barlow, DH, ed. Clinical Handbook of Psychological Disorders. 3rd ed. New York: Guilford Press; 2001.Google Scholar
65.Hofmann, SG, Tompson, MC, eds. Treating Chronic and Severe Mental Disorders: A Handbook of Empirically Supported Interventions. New York, NY: Guilford Press; 2002.Google Scholar
66.Land, C, Riccio, D. D-cycloserine: effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem. 1999;72:158–168.CrossRefGoogle ScholarPubMed
67.Pussinen, R, Sirvio, J. Effects of D-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J Psychopharmacol. 1999;13:171–179.CrossRefGoogle ScholarPubMed
68.Lelong, V, Dauphin, F, Boulouard, M. RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology. 2001;41:517–522.CrossRefGoogle ScholarPubMed
69.Pitkanen, M, Sirvio, J, MacDonald, E, Niemi, S, Ekonsalo, T, Riekkinen, P Sr. European Neuropsychopharmacology. 1995;5:457–63.Google Scholar